nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—CYP2C19—Cyclosporine—focal segmental glomerulosclerosis	0.178	0.325	CbGbCtD
Etoricoxib—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.148	0.27	CbGbCtD
Etoricoxib—CYP2D6—Cyclosporine—focal segmental glomerulosclerosis	0.135	0.247	CbGbCtD
Etoricoxib—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0858	0.157	CbGbCtD
Etoricoxib—Gingival disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0384	0.111	CcSEcCtD
Etoricoxib—Skin infection—Cyclosporine—focal segmental glomerulosclerosis	0.012	0.0345	CcSEcCtD
Etoricoxib—Nephrotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.0114	0.0328	CcSEcCtD
Etoricoxib—Bacterial infection—Cyclosporine—focal segmental glomerulosclerosis	0.00783	0.0226	CcSEcCtD
Etoricoxib—Trauma—Cyclosporine—focal segmental glomerulosclerosis	0.0076	0.0219	CcSEcCtD
Etoricoxib—Bursitis—Cyclosporine—focal segmental glomerulosclerosis	0.00748	0.0216	CcSEcCtD
Etoricoxib—Nephropathy toxic—Cyclosporine—focal segmental glomerulosclerosis	0.0063	0.0182	CcSEcCtD
Etoricoxib—Vemurafenib—ALB—focal segmental glomerulosclerosis	0.006	0.478	CrCbGaD
Etoricoxib—Polyp—Cyclosporine—focal segmental glomerulosclerosis	0.00595	0.0171	CcSEcCtD
Etoricoxib—Serum creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00588	0.017	CcSEcCtD
Etoricoxib—Folliculitis—Cyclosporine—focal segmental glomerulosclerosis	0.00575	0.0166	CcSEcCtD
Etoricoxib—Cyst—Cyclosporine—focal segmental glomerulosclerosis	0.00541	0.0156	CcSEcCtD
Etoricoxib—Peptic ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00541	0.0156	CcSEcCtD
Etoricoxib—Tongue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00497	0.0143	CcSEcCtD
Etoricoxib—Herpes zoster—Cyclosporine—focal segmental glomerulosclerosis	0.0048	0.0138	CcSEcCtD
Etoricoxib—Fungal infection—Cyclosporine—focal segmental glomerulosclerosis	0.00468	0.0135	CcSEcCtD
Etoricoxib—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.00468	0.0135	CcSEcCtD
Etoricoxib—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00465	0.0134	CcSEcCtD
Etoricoxib—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.00424	0.0122	CcSEcCtD
Etoricoxib—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.00398	0.0115	CcSEcCtD
Etoricoxib—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.00393	0.0113	CcSEcCtD
Etoricoxib—Nocturia—Cyclosporine—focal segmental glomerulosclerosis	0.0039	0.0112	CcSEcCtD
Etoricoxib—Cataract—Cyclosporine—focal segmental glomerulosclerosis	0.0038	0.011	CcSEcCtD
Etoricoxib—PTGS2—Overview of nanoparticle effects—COL4A1—focal segmental glomerulosclerosis	0.0037	0.039	CbGpPWpGaD
Etoricoxib—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.00368	0.0106	CcSEcCtD
Etoricoxib—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00355	0.0102	CcSEcCtD
Etoricoxib—Celecoxib—ALB—focal segmental glomerulosclerosis	0.00353	0.281	CrCbGaD
Etoricoxib—Blood urea increased—Cyclosporine—focal segmental glomerulosclerosis	0.00341	0.00985	CcSEcCtD
Etoricoxib—Neuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.0034	0.00979	CcSEcCtD
Etoricoxib—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.00327	0.00943	CcSEcCtD
Etoricoxib—MAPK14—IL6-mediated signaling events—PIAS1—focal segmental glomerulosclerosis	0.00305	0.0322	CbGpPWpGaD
Etoricoxib—Vismodegib—ALB—focal segmental glomerulosclerosis	0.00302	0.241	CrCbGaD
Etoricoxib—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00302	0.0087	CcSEcCtD
Etoricoxib—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.00296	0.00854	CcSEcCtD
Etoricoxib—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.00292	0.00842	CcSEcCtD
Etoricoxib—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00292	0.00842	CcSEcCtD
Etoricoxib—Injury—Cyclosporine—focal segmental glomerulosclerosis	0.00286	0.00824	CcSEcCtD
Etoricoxib—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.00277	0.00799	CcSEcCtD
Etoricoxib—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00276	0.00795	CcSEcCtD
Etoricoxib—MAPK14—Interferon type I signaling pathways—PIAS1—focal segmental glomerulosclerosis	0.00273	0.0288	CbGpPWpGaD
Etoricoxib—Anaphylactoid reaction—Cyclosporine—focal segmental glomerulosclerosis	0.00271	0.00782	CcSEcCtD
Etoricoxib—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00246	0.00709	CcSEcCtD
Etoricoxib—MAPK14—ADP signalling through P2Y purinoceptor 1—GNAQ—focal segmental glomerulosclerosis	0.00241	0.0255	CbGpPWpGaD
Etoricoxib—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00237	0.00684	CcSEcCtD
Etoricoxib—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.00236	0.00682	CcSEcCtD
Etoricoxib—MAPK14—S1P2 pathway—GNAQ—focal segmental glomerulosclerosis	0.00234	0.0247	CbGpPWpGaD
Etoricoxib—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.00232	0.0067	CcSEcCtD
Etoricoxib—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.00232	0.00668	CcSEcCtD
Etoricoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—ANGPT2—focal segmental glomerulosclerosis	0.00232	0.0244	CbGpPWpGaD
Etoricoxib—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.00228	0.00659	CcSEcCtD
Etoricoxib—Bronchospasm—Cyclosporine—focal segmental glomerulosclerosis	0.00223	0.00644	CcSEcCtD
Etoricoxib—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00222	0.00641	CcSEcCtD
Etoricoxib—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.00218	0.00629	CcSEcCtD
Etoricoxib—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00218	0.00627	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00211	0.00608	CcSEcCtD
Etoricoxib—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.00207	0.00595	CcSEcCtD
Etoricoxib—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00205	0.0059	CcSEcCtD
Etoricoxib—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.00204	0.00587	CcSEcCtD
Etoricoxib—MAPK14—Signal amplification—GNAQ—focal segmental glomerulosclerosis	0.00203	0.0215	CbGpPWpGaD
Etoricoxib—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00202	0.00583	CcSEcCtD
Etoricoxib—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00202	0.00583	CcSEcCtD
Etoricoxib—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00199	0.00575	CcSEcCtD
Etoricoxib—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.00199	0.00573	CcSEcCtD
Etoricoxib—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.00198	0.00572	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.00198	0.00572	CcSEcCtD
Etoricoxib—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00197	0.00569	CcSEcCtD
Etoricoxib—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.00197	0.00569	CcSEcCtD
Etoricoxib—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00197	0.00567	CcSEcCtD
Etoricoxib—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00197	0.00567	CcSEcCtD
Etoricoxib—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00193	0.00556	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00191	0.00552	CcSEcCtD
Etoricoxib—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00191	0.0055	CcSEcCtD
Etoricoxib—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.0019	0.00547	CcSEcCtD
Etoricoxib—MAPK14—Physiological and Pathological Hypertrophy  of the Heart—EDN1—focal segmental glomerulosclerosis	0.00187	0.0198	CbGpPWpGaD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—ANGPT2—focal segmental glomerulosclerosis	0.00183	0.0193	CbGpPWpGaD
Etoricoxib—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.00183	0.00526	CcSEcCtD
Etoricoxib—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00182	0.00524	CcSEcCtD
Etoricoxib—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00182	0.00524	CcSEcCtD
Etoricoxib—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00181	0.00521	CcSEcCtD
Etoricoxib—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.0018	0.0052	CcSEcCtD
Etoricoxib—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00179	0.00517	CcSEcCtD
Etoricoxib—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00178	0.00515	CcSEcCtD
Etoricoxib—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00178	0.00513	CcSEcCtD
Etoricoxib—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00175	0.00505	CcSEcCtD
Etoricoxib—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.00169	0.00488	CcSEcCtD
Etoricoxib—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.00169	0.00486	CcSEcCtD
Etoricoxib—MAPK14—Cell-Cell communication—CD2AP—focal segmental glomerulosclerosis	0.00167	0.0177	CbGpPWpGaD
Etoricoxib—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00165	0.00475	CcSEcCtD
Etoricoxib—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00164	0.00472	CcSEcCtD
Etoricoxib—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.00162	0.00468	CcSEcCtD
Etoricoxib—MAPK14—Cell-Cell communication—ACTN4—focal segmental glomerulosclerosis	0.00161	0.017	CbGpPWpGaD
Etoricoxib—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.00161	0.00463	CcSEcCtD
Etoricoxib—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00159	0.00459	CcSEcCtD
Etoricoxib—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00158	0.00456	CcSEcCtD
Etoricoxib—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.00156	0.00449	CcSEcCtD
Etoricoxib—MAPK14—Physiological and Pathological Hypertrophy  of the Heart—AGT—focal segmental glomerulosclerosis	0.00155	0.0164	CbGpPWpGaD
Etoricoxib—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.00155	0.00446	CcSEcCtD
Etoricoxib—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.00152	0.00438	CcSEcCtD
Etoricoxib—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.00149	0.0043	CcSEcCtD
Etoricoxib—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00148	0.00427	CcSEcCtD
Etoricoxib—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00146	0.00421	CcSEcCtD
Etoricoxib—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.00145	0.00419	CcSEcCtD
Etoricoxib—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.00144	0.00417	CcSEcCtD
Etoricoxib—MAPK14—VEGFR3 signaling in lymphatic endothelium—FN1—focal segmental glomerulosclerosis	0.00144	0.0152	CbGpPWpGaD
Etoricoxib—MAPK14—Cell-Cell communication—NPHS1—focal segmental glomerulosclerosis	0.00139	0.0146	CbGpPWpGaD
Etoricoxib—MAPK14—CD40/CD40L signaling—CD40LG—focal segmental glomerulosclerosis	0.00138	0.0146	CbGpPWpGaD
Etoricoxib—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.00138	0.00398	CcSEcCtD
Etoricoxib—MAPK14—Endothelins—TRPC6—focal segmental glomerulosclerosis	0.00138	0.0146	CbGpPWpGaD
Etoricoxib—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.00137	0.00394	CcSEcCtD
Etoricoxib—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.00135	0.00388	CcSEcCtD
Etoricoxib—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.00135	0.00388	CcSEcCtD
Etoricoxib—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.00134	0.00387	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00134	0.00385	CcSEcCtD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—PIAS1—focal segmental glomerulosclerosis	0.00134	0.0141	CbGpPWpGaD
Etoricoxib—MAPK14—p73 transcription factor network—WT1—focal segmental glomerulosclerosis	0.00133	0.014	CbGpPWpGaD
Etoricoxib—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.00132	0.0038	CcSEcCtD
Etoricoxib—MAPK14—Nanoparticle-mediated activation of receptor signaling—FN1—focal segmental glomerulosclerosis	0.00131	0.0138	CbGpPWpGaD
Etoricoxib—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.0013	0.00375	CcSEcCtD
Etoricoxib—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.00372	CcSEcCtD
Etoricoxib—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.00372	CcSEcCtD
Etoricoxib—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.00128	0.0037	CcSEcCtD
Etoricoxib—MAPK14—Monoamine Transport—AGT—focal segmental glomerulosclerosis	0.00128	0.0135	CbGpPWpGaD
Etoricoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—AGTR1—focal segmental glomerulosclerosis	0.00127	0.0134	CbGpPWpGaD
Etoricoxib—MAPK14—Thromboxane A2 receptor signaling—GNAQ—focal segmental glomerulosclerosis	0.00127	0.0134	CbGpPWpGaD
Etoricoxib—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00127	0.00365	CcSEcCtD
Etoricoxib—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00126	0.00364	CcSEcCtD
Etoricoxib—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00125	0.00361	CcSEcCtD
Etoricoxib—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.00123	0.00355	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00118	0.00339	CcSEcCtD
Etoricoxib—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00117	0.00337	CcSEcCtD
Etoricoxib—MAPK14—Platelet homeostasis—TRPC6—focal segmental glomerulosclerosis	0.00116	0.0123	CbGpPWpGaD
Etoricoxib—MAPK14—Endothelins—GNAQ—focal segmental glomerulosclerosis	0.00115	0.0122	CbGpPWpGaD
Etoricoxib—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.00115	0.00332	CcSEcCtD
Etoricoxib—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.00115	0.00331	CcSEcCtD
Etoricoxib—PTGS2—Overview of nanoparticle effects—FN1—focal segmental glomerulosclerosis	0.00114	0.0121	CbGpPWpGaD
Etoricoxib—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.00114	0.00328	CcSEcCtD
Etoricoxib—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00112	0.00323	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.00321	CcSEcCtD
Etoricoxib—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.00321	CcSEcCtD
Etoricoxib—MAPK14—TSH signaling pathway—GNAQ—focal segmental glomerulosclerosis	0.00111	0.0117	CbGpPWpGaD
Etoricoxib—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.0011	0.00318	CcSEcCtD
Etoricoxib—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.0011	0.00318	CcSEcCtD
Etoricoxib—MAPK14—Signaling mediated by p38-alpha and p38-beta—NOS2—focal segmental glomerulosclerosis	0.00108	0.0114	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00106	0.00307	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00106	0.00304	CcSEcCtD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—ACTN4—focal segmental glomerulosclerosis	0.00105	0.0111	CbGpPWpGaD
Etoricoxib—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—focal segmental glomerulosclerosis	0.00105	0.0111	CbGpPWpGaD
Etoricoxib—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—focal segmental glomerulosclerosis	0.00103	0.0109	CbGpPWpGaD
Etoricoxib—MAPK14—BCR signaling pathway—CD79A—focal segmental glomerulosclerosis	0.00103	0.0109	CbGpPWpGaD
Etoricoxib—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.00103	0.00296	CcSEcCtD
Etoricoxib—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00102	0.00294	CcSEcCtD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.000995	0.0105	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000951	0.00274	CcSEcCtD
Etoricoxib—MAPK14—Angiogenesis—MMP9—focal segmental glomerulosclerosis	0.000946	0.00998	CbGpPWpGaD
Etoricoxib—MAPK14—FGF signaling pathway—SPP1—focal segmental glomerulosclerosis	0.000929	0.00981	CbGpPWpGaD
Etoricoxib—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000926	0.00267	CcSEcCtD
Etoricoxib—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000913	0.00263	CcSEcCtD
Etoricoxib—MAPK14—IL4-mediated signaling events—CD40LG—focal segmental glomerulosclerosis	0.000895	0.00945	CbGpPWpGaD
Etoricoxib—MAPK14—Endothelins—EDN1—focal segmental glomerulosclerosis	0.000894	0.00943	CbGpPWpGaD
Etoricoxib—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000883	0.00255	CcSEcCtD
Etoricoxib—PTGS2—Spinal Cord Injury—COL4A1—focal segmental glomerulosclerosis	0.000858	0.00906	CbGpPWpGaD
Etoricoxib—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000853	0.00246	CcSEcCtD
Etoricoxib—MAPK14—Corticotropin-releasing hormone—GNAQ—focal segmental glomerulosclerosis	0.000852	0.00899	CbGpPWpGaD
Etoricoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—FN1—focal segmental glomerulosclerosis	0.000825	0.00871	CbGpPWpGaD
Etoricoxib—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000821	0.00237	CcSEcCtD
Etoricoxib—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000814	0.00235	CcSEcCtD
Etoricoxib—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000813	0.00234	CcSEcCtD
Etoricoxib—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000808	0.00233	CcSEcCtD
Etoricoxib—CYP2C19—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	0.000772	0.00814	CbGpPWpGaD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—CD79A—focal segmental glomerulosclerosis	0.000767	0.0081	CbGpPWpGaD
Etoricoxib—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000767	0.00221	CcSEcCtD
Etoricoxib—MAPK14—ATF-2 transcription factor network—NOS2—focal segmental glomerulosclerosis	0.000714	0.00754	CbGpPWpGaD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—LPL—focal segmental glomerulosclerosis	0.000713	0.00752	CbGpPWpGaD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—EDN1—focal segmental glomerulosclerosis	0.00071	0.0075	CbGpPWpGaD
Etoricoxib—CYP2D6—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	0.00071	0.00749	CbGpPWpGaD
Etoricoxib—CYP2E1—Vitamin A and Carotenoid Metabolism—LPL—focal segmental glomerulosclerosis	0.000708	0.00747	CbGpPWpGaD
Etoricoxib—MAPK14—IL12-mediated signaling events—NOS2—focal segmental glomerulosclerosis	0.000704	0.00743	CbGpPWpGaD
Etoricoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—MMP2—focal segmental glomerulosclerosis	0.000699	0.00738	CbGpPWpGaD
Etoricoxib—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—focal segmental glomerulosclerosis	0.000693	0.00731	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—focal segmental glomerulosclerosis	0.000679	0.00717	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000657	0.00693	CbGpPWpGaD
Etoricoxib—MAPK14—AGE/RAGE pathway—NOS2—focal segmental glomerulosclerosis	0.000653	0.00689	CbGpPWpGaD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—FN1—focal segmental glomerulosclerosis	0.000653	0.00689	CbGpPWpGaD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—NOS2—focal segmental glomerulosclerosis	0.000645	0.00681	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.000635	0.00671	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—MYH10—focal segmental glomerulosclerosis	0.000629	0.00663	CbGpPWpGaD
Etoricoxib—MAPK14—ATF-2 transcription factor network—MMP2—focal segmental glomerulosclerosis	0.000613	0.00647	CbGpPWpGaD
Etoricoxib—MAPK14—TWEAK Signaling Pathway—MMP9—focal segmental glomerulosclerosis	0.000604	0.00638	CbGpPWpGaD
Etoricoxib—CYP1A2—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	0.000601	0.00634	CbGpPWpGaD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—AGT—focal segmental glomerulosclerosis	0.000589	0.00622	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet homeostasis—NOS2—focal segmental glomerulosclerosis	0.000571	0.00603	CbGpPWpGaD
Etoricoxib—MAPK14—AGE/RAGE pathway—MMP2—focal segmental glomerulosclerosis	0.00056	0.00591	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—SPP1—focal segmental glomerulosclerosis	0.000559	0.0059	CbGpPWpGaD
Etoricoxib—MAPK14—Oncostatin M Signaling Pathway—SERPINE1—focal segmental glomerulosclerosis	0.000556	0.00587	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—ACTN4—focal segmental glomerulosclerosis	0.000543	0.00573	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—PCNA—focal segmental glomerulosclerosis	0.000536	0.00566	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	0.000505	0.00533	CbGpPWpGaD
Etoricoxib—MAPK14—FGF signaling pathway—MMP9—focal segmental glomerulosclerosis	0.000494	0.00522	CbGpPWpGaD
Etoricoxib—MAPK14—p73 transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.000476	0.00502	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—COL4A4—focal segmental glomerulosclerosis	0.000465	0.00491	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—FN1—focal segmental glomerulosclerosis	0.000456	0.00481	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—SPP1—focal segmental glomerulosclerosis	0.000436	0.0046	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—COL4A1—focal segmental glomerulosclerosis	0.000427	0.00451	CbGpPWpGaD
Etoricoxib—MAPK14—BDNF signaling pathway—SPP1—focal segmental glomerulosclerosis	0.000424	0.00448	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	0.000422	0.00446	CbGpPWpGaD
Etoricoxib—MAPK14—AGE/RAGE pathway—MMP9—focal segmental glomerulosclerosis	0.000421	0.00444	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000419	0.00443	CbGpPWpGaD
Etoricoxib—MAPK14—Cardiac Progenitor Differentiation—TGFB1—focal segmental glomerulosclerosis	0.000414	0.00436	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—LPL—focal segmental glomerulosclerosis	0.000403	0.00426	CbGpPWpGaD
Etoricoxib—MAPK14—Cardiac Hypertrophic Response—TGFB1—focal segmental glomerulosclerosis	0.000401	0.00424	CbGpPWpGaD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—FN1—focal segmental glomerulosclerosis	0.000379	0.004	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—SERPINE1—focal segmental glomerulosclerosis	0.000379	0.004	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—PCNA—focal segmental glomerulosclerosis	0.000379	0.004	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	0.000363	0.00384	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—COL4A3—focal segmental glomerulosclerosis	0.000361	0.00381	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—MYH9—focal segmental glomerulosclerosis	0.000344	0.00364	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000332	0.0035	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—MYH9—focal segmental glomerulosclerosis	0.000304	0.00321	CbGpPWpGaD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—focal segmental glomerulosclerosis	0.000286	0.00302	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	0.000279	0.00294	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—ALB—focal segmental glomerulosclerosis	0.000278	0.00294	CbGpPWpGaD
Etoricoxib—MAPK14—TCR Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	0.000271	0.00286	CbGpPWpGaD
Etoricoxib—MAPK14—Corticotropin-releasing hormone—TGFB1—focal segmental glomerulosclerosis	0.000266	0.00281	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—TRPC6—focal segmental glomerulosclerosis	0.000266	0.0028	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—NOS2—focal segmental glomerulosclerosis	0.000262	0.00276	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—TRPC6—focal segmental glomerulosclerosis	0.00026	0.00275	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	0.000251	0.00265	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—TGFB1—focal segmental glomerulosclerosis	0.000239	0.00253	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PIAS1—focal segmental glomerulosclerosis	0.000239	0.00252	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—GNAQ—focal segmental glomerulosclerosis	0.000218	0.0023	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000212	0.00224	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	0.000209	0.00221	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—ALB—focal segmental glomerulosclerosis	0.000209	0.0022	CbGpPWpGaD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	0.000199	0.0021	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MYH9—focal segmental glomerulosclerosis	0.000177	0.00187	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—MMP9—focal segmental glomerulosclerosis	0.000169	0.00178	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	0.000167	0.00177	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—LPL—focal segmental glomerulosclerosis	0.000167	0.00176	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	0.000164	0.00173	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000156	0.00165	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000155	0.00163	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	0.000148	0.00157	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000142	0.0015	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—TGFB1—focal segmental glomerulosclerosis	0.000139	0.00147	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000137	0.00145	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	0.000132	0.00139	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—FN1—focal segmental glomerulosclerosis	0.000129	0.00137	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—NOS2—focal segmental glomerulosclerosis	0.000128	0.00135	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—CTGF—focal segmental glomerulosclerosis	0.000123	0.0013	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.00012	0.00127	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000113	0.0012	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—MMP2—focal segmental glomerulosclerosis	0.000112	0.00118	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	0.000108	0.00114	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—ALB—focal segmental glomerulosclerosis	0.000108	0.00113	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD79A—focal segmental glomerulosclerosis	0.000107	0.00113	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000103	0.00109	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	9.98e-05	0.00105	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	9.53e-05	0.00101	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	9.47e-05	0.001	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	9.1e-05	0.000961	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	8.83e-05	0.000932	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	8.83e-05	0.000932	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	8.78e-05	0.000927	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD40LG—focal segmental glomerulosclerosis	8.75e-05	0.000924	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—MMP9—focal segmental glomerulosclerosis	8.41e-05	0.000888	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	8.15e-05	0.00086	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	7.78e-05	0.000821	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	7.38e-05	0.000779	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—LIPC—focal segmental glomerulosclerosis	6.95e-05	0.000734	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	6.93e-05	0.000732	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	6.92e-05	0.00073	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—TGFB1—focal segmental glomerulosclerosis	6.8e-05	0.000718	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	6.75e-05	0.000713	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—LIPC—focal segmental glomerulosclerosis	6.55e-05	0.000691	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	6.31e-05	0.000666	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	6.25e-05	0.00066	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CTGF—focal segmental glomerulosclerosis	6.12e-05	0.000646	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	5.92e-05	0.000625	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CTGF—focal segmental glomerulosclerosis	5.76e-05	0.000608	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	5.72e-05	0.000604	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.64e-05	0.000595	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	5.62e-05	0.000593	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.55e-05	0.000586	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	5.4e-05	0.00057	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	5.39e-05	0.000569	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.31e-05	0.00056	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.26e-05	0.000555	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—LPL—focal segmental glomerulosclerosis	5.07e-05	0.000535	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—LIPC—focal segmental glomerulosclerosis	5.05e-05	0.000533	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.75e-05	0.000501	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	4.64e-05	0.00049	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	4.61e-05	0.000487	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—LIPC—focal segmental glomerulosclerosis	4.6e-05	0.000486	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	4.54e-05	0.000479	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CTGF—focal segmental glomerulosclerosis	4.45e-05	0.000469	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.39e-05	0.000463	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—LPL—focal segmental glomerulosclerosis	4.24e-05	0.000448	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	4.14e-05	0.000437	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.1e-05	0.000432	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	4.09e-05	0.000432	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CTGF—focal segmental glomerulosclerosis	4.05e-05	0.000428	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—LPL—focal segmental glomerulosclerosis	3.99e-05	0.000422	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NOS2—focal segmental glomerulosclerosis	3.96e-05	0.000418	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	3.93e-05	0.000415	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.77e-05	0.000398	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.73e-05	0.000394	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.65e-05	0.000386	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—AGT—focal segmental glomerulosclerosis	3.63e-05	0.000383	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	3.54e-05	0.000374	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	3.46e-05	0.000366	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—AGT—focal segmental glomerulosclerosis	3.42e-05	0.000361	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—SERPINE1—focal segmental glomerulosclerosis	3.33e-05	0.000352	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.19e-05	0.000337	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—LPL—focal segmental glomerulosclerosis	3.08e-05	0.000325	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	3.04e-05	0.00032	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	2.83e-05	0.000299	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—LPL—focal segmental glomerulosclerosis	2.81e-05	0.000297	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.8e-05	0.000295	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ALB—focal segmental glomerulosclerosis	2.79e-05	0.000294	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	2.67e-05	0.000282	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—AGT—focal segmental glomerulosclerosis	2.64e-05	0.000278	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ALB—focal segmental glomerulosclerosis	2.62e-05	0.000277	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.46e-05	0.00026	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	2.42e-05	0.000256	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—AGT—focal segmental glomerulosclerosis	2.4e-05	0.000254	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—LPL—focal segmental glomerulosclerosis	2.4e-05	0.000253	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.31e-05	0.000243	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TGFB1—focal segmental glomerulosclerosis	2.1e-05	0.000222	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—AGT—focal segmental glomerulosclerosis	2.05e-05	0.000217	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ALB—focal segmental glomerulosclerosis	2.02e-05	0.000214	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	1.86e-05	0.000196	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	1.85e-05	0.000196	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ALB—focal segmental glomerulosclerosis	1.84e-05	0.000195	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	1.59e-05	0.000167	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ALB—focal segmental glomerulosclerosis	1.58e-05	0.000166	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	1.22e-05	0.000128	CbGpPWpGaD
